CN1051310C - 呋喃基或噻吩基羰基取代的紫杉烷及含它们的药用组合物 - Google Patents
呋喃基或噻吩基羰基取代的紫杉烷及含它们的药用组合物 Download PDFInfo
- Publication number
- CN1051310C CN1051310C CN93114654A CN93114654A CN1051310C CN 1051310 C CN1051310 C CN 1051310C CN 93114654 A CN93114654 A CN 93114654A CN 93114654 A CN93114654 A CN 93114654A CN 1051310 C CN1051310 C CN 1051310C
- Authority
- CN
- China
- Prior art keywords
- hydrogen
- tool
- taxane derivative
- alkyl group
- low alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 125000002541 furyl group Chemical group 0.000 title claims abstract description 11
- 229940123237 Taxane Drugs 0.000 title description 2
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract description 24
- 239000001257 hydrogen Substances 0.000 claims abstract description 21
- 150000002431 hydrogen Chemical group 0.000 claims abstract description 15
- DKPFODGZWDEEBT-QFIAKTPHSA-N taxane Chemical class C([C@]1(C)CCC[C@@H](C)[C@H]1C1)C[C@H]2[C@H](C)CC[C@@H]1C2(C)C DKPFODGZWDEEBT-QFIAKTPHSA-N 0.000 claims abstract description 15
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims abstract description 6
- 125000000636 p-nitrophenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)[N+]([O-])=O 0.000 claims abstract description 6
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims abstract description 6
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 claims abstract description 5
- 125000001544 thienyl group Chemical group 0.000 claims abstract description 5
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims abstract description 4
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims abstract description 4
- 239000000203 mixture Substances 0.000 claims description 31
- -1 ethylene, propylene Chemical group 0.000 claims description 16
- 125000000217 alkyl group Chemical group 0.000 claims description 12
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 9
- 229910052799 carbon Inorganic materials 0.000 claims description 9
- 125000004432 carbon atom Chemical group C* 0.000 claims description 8
- 125000002030 1,2-phenylene group Chemical group [H]C1=C([H])C([*:1])=C([*:2])C([H])=C1[H] 0.000 claims description 3
- GAWIXWVDTYZWAW-UHFFFAOYSA-N C[CH]O Chemical group C[CH]O GAWIXWVDTYZWAW-UHFFFAOYSA-N 0.000 claims description 3
- 229910052736 halogen Inorganic materials 0.000 claims description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 3
- 150000001721 carbon Chemical group 0.000 claims 4
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 2
- 230000035479 physiological effects, processes and functions Effects 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 abstract description 5
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract description 4
- 125000000524 functional group Chemical group 0.000 abstract description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract description 2
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 1
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 34
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 27
- 239000000243 solution Substances 0.000 description 22
- 229930012538 Paclitaxel Natural products 0.000 description 21
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 20
- 229960001592 paclitaxel Drugs 0.000 description 19
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 18
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 17
- OVMSOCFBDVBLFW-VHLOTGQHSA-N 5beta,20-epoxy-1,7beta,13alpha-trihydroxy-9-oxotax-11-ene-2alpha,4alpha,10beta-triyl 4,10-diacetate 2-benzoate Chemical compound O([C@@H]1[C@@]2(C[C@H](O)C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)O)C(=O)C1=CC=CC=C1 OVMSOCFBDVBLFW-VHLOTGQHSA-N 0.000 description 16
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 14
- 210000004027 cell Anatomy 0.000 description 13
- 238000006243 chemical reaction Methods 0.000 description 13
- 150000001875 compounds Chemical class 0.000 description 10
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 9
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- 150000003952 β-lactams Chemical class 0.000 description 8
- 229910052751 metal Inorganic materials 0.000 description 7
- 239000002184 metal Substances 0.000 description 7
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 6
- 150000004703 alkoxides Chemical class 0.000 description 6
- 238000001704 evaporation Methods 0.000 description 6
- 230000008020 evaporation Effects 0.000 description 6
- 239000012047 saturated solution Substances 0.000 description 6
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 5
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 229940063683 taxotere Drugs 0.000 description 5
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 4
- 102000004243 Tubulin Human genes 0.000 description 4
- 108090000704 Tubulin Proteins 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 208000032839 leukemia Diseases 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 238000001953 recrystallisation Methods 0.000 description 4
- 239000000375 suspending agent Substances 0.000 description 4
- 238000005160 1H NMR spectroscopy Methods 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 229940034982 antineoplastic agent Drugs 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 238000011097 chromatography purification Methods 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- MTZQAGJQAFMTAQ-UHFFFAOYSA-N ethyl benzoate Chemical compound CCOC(=O)C1=CC=CC=C1 MTZQAGJQAFMTAQ-UHFFFAOYSA-N 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- 239000012044 organic layer Substances 0.000 description 3
- WSDQIHATCCOMLH-UHFFFAOYSA-N phenyl n-(3,5-dichlorophenyl)carbamate Chemical compound ClC1=CC(Cl)=CC(NC(=O)OC=2C=CC=CC=2)=C1 WSDQIHATCCOMLH-UHFFFAOYSA-N 0.000 description 3
- 239000000741 silica gel Substances 0.000 description 3
- 229910002027 silica gel Inorganic materials 0.000 description 3
- 235000017557 sodium bicarbonate Nutrition 0.000 description 3
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 125000001424 substituent group Chemical group 0.000 description 3
- KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical compound NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 description 2
- 206010009944 Colon cancer Diseases 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 238000007205 Parnes methylation reaction Methods 0.000 description 2
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 239000003513 alkali Substances 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- 229910052786 argon Inorganic materials 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000007795 chemical reaction product Substances 0.000 description 2
- 208000029742 colonic neoplasm Diseases 0.000 description 2
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 239000003701 inert diluent Substances 0.000 description 2
- 235000012204 lemonade/lime carbonate Nutrition 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 229910044991 metal oxide Inorganic materials 0.000 description 2
- 150000002902 organometallic compounds Chemical class 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 150000004579 taxol derivatives Chemical class 0.000 description 2
- 125000003831 tetrazolyl group Chemical group 0.000 description 2
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- UHBXGHADNVDXMM-UHFFFAOYSA-N C(C)(C)N(C(C)C)CC[Li] Chemical compound C(C)(C)N(C(C)C)CC[Li] UHBXGHADNVDXMM-UHFFFAOYSA-N 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000978776 Senegalia senegal Species 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 125000002490 anilino group Chemical group [H]N(*)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 230000000118 anti-neoplastic effect Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 239000000305 astragalus gummifer gum Substances 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000008033 biological extinction Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 239000004403 ethyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010228 ethyl p-hydroxybenzoate Nutrition 0.000 description 1
- 229940043351 ethyl-p-hydroxybenzoate Drugs 0.000 description 1
- NUVBSKCKDOMJSU-UHFFFAOYSA-N ethylparaben Chemical compound CCOC(=O)C1=CC=C(O)C=C1 NUVBSKCKDOMJSU-UHFFFAOYSA-N 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000003979 granulating agent Substances 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 229920000591 gum Polymers 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000036457 multidrug resistance Effects 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 229940026778 other chemotherapeutics in atc Drugs 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 125000006239 protecting group Chemical group 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 235000017550 sodium carbonate Nutrition 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- NRUKOCRGYNPUPR-QBPJDGROSA-N teniposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@@H](OC[C@H]4O3)C=3SC=CC=3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 NRUKOCRGYNPUPR-QBPJDGROSA-N 0.000 description 1
- 229960001278 teniposide Drugs 0.000 description 1
- 150000003505 terpenes Chemical class 0.000 description 1
- 235000007586 terpenes Nutrition 0.000 description 1
- 125000006633 tert-butoxycarbonylamino group Chemical group 0.000 description 1
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 229930192474 thiophene Natural products 0.000 description 1
- 229910052719 titanium Inorganic materials 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 229910052723 transition metal Inorganic materials 0.000 description 1
- 150000003624 transition metals Chemical class 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- QXTIBZLKQPJVII-UHFFFAOYSA-N triethylsilicon Chemical compound CC[Si](CC)CC QXTIBZLKQPJVII-UHFFFAOYSA-N 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
- C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C227/00—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C227/22—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton from lactams, cyclic ketones or cyclic oximes, e.g. by reactions involving Beckmann rearrangement
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C231/00—Preparation of carboxylic acid amides
- C07C231/12—Preparation of carboxylic acid amides by reactions not involving the formation of carboxamide groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/64—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings
- C07C233/81—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups
- C07C233/82—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
- C07C233/87—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom of a carbon skeleton containing six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D305/00—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms
- C07D305/14—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
- C07F7/1804—Compounds having Si-O-C linkages
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/14—The ring being saturated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/16—Systems containing only non-condensed rings with a six-membered ring the ring being unsaturated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2603/00—Systems containing at least three condensed rings
- C07C2603/56—Ring systems containing bridged rings
- C07C2603/58—Ring systems containing bridged rings containing three rings
- C07C2603/60—Ring systems containing bridged rings containing three rings containing at least one ring with less than six members
- C07C2603/62—Ring systems containing bridged rings containing three rings containing at least one ring with less than six members containing three- or four-membered rings
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Epoxy Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
结构如下所示的紫杉烷衍生物可用作抗肿瘤剂,式中R1、R3、T1、T2、Ac、E1和E2的定义见说明书:
Description
本发明涉及可用作抗白血病及抗肿瘤剂的新的紫杉烷(taxanes)。
紫杉烷萜类在生物和化学领域均引起了人们极大的兴趣。紫杉醇(taxol)是其中之一。紫杉醇是一个有希望的具广谱抗白血病和抑制肿瘤活性的癌症化疗剂。紫杉醇具2′R,3′S构型,其结构式如下式(1)示:其中Ac是乙酰基。由于其有前途的活性,目前法国和美国都在对紫杉醇进行临床试验。
Colin等人在美国专利第4814470中报道,具下式(2)结构的紫杉醇衍生物,其活性远远大于紫杉醇(1)的活性。所述式(2)结构如下:式中R′代表氢或乙酰基,以及R″和R中一个代表羟基,而另一个代表叔丁氧基羰基氨基及其立体异构形式和它们的混合物。式中R″是羟基、R是叔丁氧基羰基氨基并具2′R、3′S构型的式(2)化合物通常称为taxotere。
尽管紫杉醇和taxotere是有希望的化疗剂,但它们并不是普遍奏效的。因此仍有必要开发其它的化疗剂。
因此,本发明的目的之一是提供新的紫杉烷衍生物,它们是有效的抗白血病和抗肿瘤剂。
其中T2是H、C1-C6烷基、C2-C6链烯基、C2-C6链炔基或单环芳基,Ac是乙酰基,以及E1和E2分别选自氢、羟基保护基团和能增加紫杉烷衍生物水溶性的功能基。
本发明的其它目的和特征将在下文中做部分叙述。
根据本发明,现已发现:一般具式(3)以及尤其是具式(4)、(5)和(6)结构的化合物在体外显示出显著的特性,是有效的抗白血病和抗肿瘤剂。其生物活性已在体外用微管蛋白测定法(tubulinassays)和人癌细胞系进行了测定,并将该活性与紫杉醇和taxotere的作了比较;所述测定方法是按照Parness等人的方法,见J.CellBiology,91:479-487(1981);所述式(4)、(5)和(6)的结构如下:
具2′R、3′S构型的式(4)、(5)和(6)紫杉烷可通过下述方法获得:使β-内酰胺与具紫杉烷四环核及C-13金属氧化物取代基的金属醇盐反应,生成在C-13位具β-酰氨基酯取代基的化合物。所述的β-内酰胺具下式(7)结构:式中R1是苯基或对硝基苯基,R2是羟基保护基团,以及R3是呋喃基或噻吩基。
试剂
(a)二异丙基氨基化锂,四氢呋喃(“THF”),-78℃-
-50℃;
(b)六甲基二硅氮杂烷(disilazane)锂,THF,-78-
0℃;
(c)THF,-78-25℃,(2小时);和
(d)三乙胺和酰基氯。
以上反应路线中所示的3-羟基保护基团是SiR5,式中R5是三烷基或三芳基,如三乙基。3-羟基可用其它标准的保护基团如1-乙氧基乙基或2,2,2-三氯乙氧基甲基来保护。更多的羟基保护基团及其合成可见“Protective Groups in Organic Synthesis”,T.W.Greene,John Wiley & Sons,1981。
外消旋β-内酰胺可以通过将其相应的2-甲氧基-2-(三氟甲基)苯基乙酸酯重结晶,而在保护前被拆分成纯的对映体。然而在下文所述的连接有β-酰氨基酯侧链的反应具很高的非对映选择性的优点,因此允许侧链前体的外消旋混合物。
具紫杉烷四环核和C-13金属氧化物取代基的金属醇盐具下式(8)结构:式中T1是氢、羟基保护基团或-COT2,T2是H、C1-C6烷基、C2-C6链烯基、C2-C6链炔基或单环芳基,T3是氢或羟基保护基团,以及M是金属,最好选自IA族、IIA族和过渡金属,以Li、Mg、Na、K或Ti为最佳。
该金属醇盐最好通过使具紫杉烷四环核和C-13羟基基团的醇在合适的溶剂中与有机金属化合物反应来制备。优选的醇是保护的浆果赤霉素III,尤其是7-0-三乙基甲硅烷基浆果赤霉素III(它可按Greene等人在JACS 110:5917(1988)中所述的方法或通过其它途径制得)或7,10-双-0-三乙基甲硅烷基浆果赤霉素III。
根据Greene等人的报道,10-去乙酰基浆果赤霉素III按照以下反应路线转化成7-0-三乙基甲硅烷基-10-去乙酰基浆果赤霉素在据报道是经仔细选择的最佳条件下,10-去乙酰基浆果赤霉素III与20当量(C2H5)3SiCl在23℃及氩气气氛中并在吡啶存在下反应20小时,得反应产物7-三乙基甲硅烷基-10-去乙酰基浆果赤霉素III(10a),纯化后收率为84-86%;所述吡啶的用量为每mmol 10-去乙酰基浆果赤霉素III 50ml。然后可将反应产物用5当量CH3COCl和吡啶在0℃以及氩气气氛下乙酰化48小时,得7-0-三乙基甲硅烷基浆果赤霉素III(10b),收率为86%;所述吡啶的用量为每mmol 10a25ml。见Greene等,JACS 110,5917-5918(1988)。
7-0-三乙基甲硅烷基浆果赤霉素III(10b)在溶剂如四氢呋喃(THF)中与有机金属化合物如正丁基锂反应,生成金属醇盐13-0-锂-7-0-三乙基甲硅烷基浆果赤霉素III(11),如以下反应图解所示:
如以下反应图解所示,13-0-锂-7-0-三乙基甲硅烷基浆果赤霉素III(11)与式中R2是三乙基甲硅烷基的β-内酰胺(7)反应,得到C-7和C-2′羟基被三乙基甲硅烷基基团保护的中间体;然后在温和的条件下,即不影响酯键或紫杉烷取代基的条件下,将三乙基甲硅烷基基团水解:式中R1是苯基或对硝基苯基,R3是呋喃基或噻吩基。
醇向金属醇盐的转化和紫杉烷衍生物的最终合成均可以在同一个反应器中进行,最好是将β-内酰胺在金属醇盐生成后加到反应器中。
本发明式(1)化合物在抑制动物、包括人的肿瘤生长方面有效,它最好以药用组合物的形式来使用;所述药用组合物包含抗肿瘤有效量的本发明化合物和药学上可接受的载体或稀释剂。
本发明抗肿瘤组合物可以配制成适合所需使用途径如口服、非胃肠道或局部给药的任何适宜的形式。非胃肠道给药的例子有肌内、静脉内、腹膜内、直肠和皮下给药。
稀释剂或载体组分不应削弱抗肿瘤化合物的治疗作用。
适宜的口服制型包括片剂、可分散的粉剂、颗粒剂、胶囊剂、悬浮剂、糖浆剂和酏剂。用于片剂的惰性稀释剂和载体包括例如碳酸钙、碳酸钠、乳糖和滑石粉。片剂也可以含有成粒剂和崩解剂如淀粉和藻酸,粘合剂如淀粉、明胶和阿拉伯胶,以及润滑剂如硬脂酸镁、硬脂酸和滑石粉。片剂可以不包衣,或可用已知技术包衣,制成延缓崩解和吸收的包衣片。可用在胶囊剂中的惰性稀释剂和载体包括例如碳酸钙、磷酸钙和高岭土。悬浮剂、糖浆剂和酏剂可含有常规赋形剂如甲基纤维素、黄蓍胶、藻酸钠,润湿剂如卵磷脂和聚氧乙烯硬脂酸酯以及防腐剂如对羟基苯甲酸乙酯。
适宜于非胃肠道给药的剂型包括溶液、悬浮剂、分散剂、乳剂等。也可将其制成可在使用前立即溶于或悬浮于灭菌注射用介质中的灭菌固体组合物。它们可以含有本领域公知的助悬剂或分散剂。
式(3)化合物的水溶性可以通过将C2′和/或C7取代基改性,与适宜的功能基E1和E2结合而得到改善。为增加水溶性,E1和E2各自可以是氢和-COGCOR1,其中G是1,2-亚乙基、1,2-亚丙基、-CH=CH-、1,2-亚环己基或1,2-亚苯基,R1是OH碱、NR2R3、OR3、SR3、OCH2CONR4R5或OH,R2是氢、甲基,R3是(CH2)nNR6R7、(CH2)nN+R6R7R8X-,n是1-3,R4是氢、具1-4个碳原子的低级烷基,R5是氢、具1-4个碳原子的低级烷基、苄基、羟基乙基、CH2CO2H、二甲基氨基乙基,R6R7是具1或2个碳原子的低级烷基、苄基或者R6与R7和NR6R7中的氮
以下实施例将举例说明本发明。
实施例1
N-去苯甲酰基-N-(呋喃甲酰)-3′-去苯基-3′-(4-硝基苯基)紫杉醇的制备
将0.174ml 1.63M nBuLi的己烷溶液于-45℃滴加至7-三乙基甲硅烷基浆果赤霉素III(200mg,0.286mmol)的THF(2ml)溶液中。在-45℃ 0.5小时后,将顺式-1-(呋喃甲酰)-3-三乙基甲硅烷氧基-4-(4-硝基苯)氮杂环丁-2-酮(596mg,1.43mmol)的THF(2ml)溶液滴加至该混合物中。将溶液温热至0℃,并在该温度下保持1小时,然后加入1ml 10%AcOH的THF溶液。将混合物分配于NaHCO3饱和溶液和60/40乙酸乙酯/己烷中。将有机层蒸发后得到的残留物经硅胶过滤纯化,得320mg混合物,该混合物含有(2′R,3′S)-2′7-(双)三乙基甲硅烷基-N-去苯甲酰基-N-(呋喃甲酰)-3′-去苯基-3′-(4-硝基苯基)紫杉醇和少量的(2′S,3′R)异构体。
将2.8ml 48%HF水溶液于0℃加至由上述反应所得的混合物(320mg,0.286mmol)的乙腈(18ml)和吡啶(0.93ml)溶液中。将混合物于0℃搅拌3小时,然后于25℃搅拌13小时后将混合物分配于碳酸氢钠饱和溶液和乙酸乙酯中。将乙酸乙酯溶液蒸发后得254mg残留物,将其用闪层析纯化,用甲醇/水重结晶,得187mg(74%)N-去苯甲酰基-N-(呋喃甲酰)-3′-去苯基-3′-(4-硝基苯基)紫杉醇。m.p.184-185℃;[α]25 Na-60.0°(c 0.006,CHCl3)。1H NMR(CDCl3,300MHz)δ8.26(d,J=8.79Hz,2H,Ar-NO2),8.12(d,J=7.2Hz,2H,苯甲酸酯,邻位),7.68(d,J=8.8Hz 2H,苯甲酰胺,邻位),7.7-7.47(m,6H,芳族的),7.3(d,J=9.3Hz,1H,NH),7.02(d,J=3.3Hz,1H,呋喃基),6.48(dd,J=3.3Hz,1.65Hz,1H,呋喃基),6.27(s,1H Hz,H10),6.26(dd,J=8.5,8.5Hz,1H,H13),5.87(dd,J=8.8,1.65Hz,1H,H3′),5.65 (d,J=6.6Hz,1H,H2β),4.93(d,J=8.2Hz,1H,H5),4.79(dd,J=2.7,1.4Hz,1H,H2′),4.38(m,1H,H7),4.29(d,J=8.4Hz,1H,H20α),4.18(d,J=8.4Hz,1H,H20β),3.97(d,J=3.3Hz,1H,2′OH),3.79(d,J=6.6Hz,1H,H3),2.5(m,1H,H6α),2.4(m,1H,7OH),2.38(s,3H,4Ac),2.27(m,2H,H14),2.22(s,3H,10Ac),1.88(m,1H,H6β),1.81(br s,3H,Me18),1.78(s,1H,1OH),1.68(s,3H,Me19),1.21(s,3H,Me17),1.13(s,3H,Me16)。
实施例2N-去苯甲酰基-N-(2-呋喃甲酰)紫杉醇的制备
将0.174ml 1.63M nBuLi的己烷溶液于-45℃滴加至7-三乙基甲硅烷基浆果赤霉素III(200mg,0.286mmol)的THF(2ml)溶液中。于-45℃0.5小时后,将顺式-1-(2-呋喃甲酰)-3-三乙基甲硅烷氧基-4-苯基氮杂环丁-2-酮(531mg,1.43mmol)的THF(2ml)溶液滴加至该混合物中。将溶液温热至0℃并在该温度下保持1小时,然后加入1ml 10%AcOH的THF溶液。将混合物分配于NaHCO3饱和溶液和60/40乙酸乙酯/己烷中。将有机层蒸发后得到的残留物用硅胶过滤纯化,得306mg混合物,该混合物含有(2′R,3′S)-2′7-(双)三乙基甲硅烷基-N-去苯甲酰基-N-(2-呋喃甲酰)紫杉醇和少量的(2′S,3′R)异构体。
将2.8ml 48%HF水溶液于0℃加至由上述反应所得的混合物(306mg,0.286mmol)的乙腈(18ml)和吡啶(0.93ml)溶液中。将混合物于0℃搅拌3小时,然后于25℃搅拌13小时后将混合物分配于碳酸氢钠饱和溶液和乙酸乙酯中。将乙酸乙酯溶液蒸发后得240mg残留物,将其用闪层析纯化,用甲醇/水重结晶,得192mg(80%)N-去苯甲酰基-N-(2-呋喃甲酰)紫杉醇。m.p.172-174℃;[α]25 Na-49.6°(c 0.0103,CHCl3)。1H NMR(CDCl3,300MHz)δ8.12(d,J=7.1Hz,2H,苯甲酸酯,邻位),7.64-7.33(m,9H,芳族的),7.19(d,J=8.8Hz,1H,NH),7.01 (d,J=3.3Hz,1H,呋喃基),6.45(dd,1H,呋喃基),6.26(s,1H,H10),6.21(dd,J=8.8,8.8Hz,1H,H13),5.72(dd,J=8.8,1.7Hz,1H,H3′),5.66(d,J=7.1Hz,1H,H2β),4.92(d,J=8.2Hz,1H,H5),4.75(brs,1H,H2′),4.40(m,1H,H7),4.28(d,J=8.2Hz,1H,H20α),4.18(d,J=8.2Hz,1H,H20β),3.78(d,J=6.6Hz,1H,H3),3.69(d,J=3.8Hz,1H,2′OH),2.53(m,1H,H6α),2.47(br s,1H,7OH),2.3 6(s,3H,4Ac),2.32(m,2H,H14),2.22(s,3H,10Ac),1.84 (m,1H,H6β),1.79(br s,3H,Me18),1.67(s,3H,Me19),1.22(s,3H,Me17),1.13(s,3H,Me16)。
将0.174ml 1.63M nBuLi的己烷溶液于-45℃滴加至7-三乙基甲硅烷基浆果赤霉素III(200mg,0.286mmol)的THF(2ml)溶液中。于-45℃ 0.5小时后,将顺式-1-(2-噻吩甲酰)-3-三乙基甲硅烷氧基-4-苯基氮杂环丁-2-酮(554mg,1.43mmol)的THF(2ml)溶液滴加至该混合物中。将溶液温热至0℃并在该温度下保持1小时,然后加入1ml 10%AcOH的THF溶液。将混合物分配于NaHCO3饱和溶液和60/40乙酸乙酯/己烷中。将有机层蒸发后得到的残留物用硅胶过滤纯化,得311mg混合物,该混合物含有(2′R,3′S)-2′7-(双)三乙基甲硅烷基-N-去苯甲酰基-N-(2-噻吩甲酰)紫杉醇和少量的(2′S,3′R)异构体。
将2.8ml 48%HF水溶液于0℃加至由上述反应所得的混合物(311mg,0.286mmol)的乙腈(18ml)和吡啶(0.93ml)溶液中。将混合物于0℃搅拌3小时,然后于25℃搅拌13小时后将混合物分配于碳酸氢钠饱和溶液和乙酸乙酯中。将乙酸乙酯溶液蒸发后得246mg残留物,将其用闪层析纯化,用甲醇/水重结晶,得195mg(80%)N-去苯甲酰基-N-(2-噻吩甲酰)紫杉醇。m.p.218-219℃;[α]25 Na-47.6°(c 0.0103,CHCl3)。1H NMR(CDCl3,300MHz)δ8.12(d,J=7.1Hz,2H,苯甲酸酯邻位),7.64-7.31(m,10H,芳族的),7.05(dd,1H,噻吩基环),6.86(d,J=9.3Hz,1H,NH),6.23(s,1H,H10),6.21(dd,J=8.8,8.8Hz,1H,H13),5.75(dd,J=8.8,2.2Hz,1H,H3′),5.66(d,J=7.1Hz,1H,H2β),4.93(dd,J=9.3,1.65Hz,1H,H5),4.78(dd,J=5.0,2.7Hz,1H,H2′),4.41(m,1H,H7),4.28(d,J=8.2Hz,1H,H20α),4.18(d,J=8.2Hz,1H,H20β),3.78(d,J=6.6Hz,1H,H3),3.63(d,J=4.9Hz,1H,2′OH),2.53(m,1H,H6α),2.48(d,J=4.4Hz,1H,7OH),2.36(s,3H,4Ac),2.30(m,2H,H14),2.23(s,3H,10Ac),1.85(m,1H,H6β),1.78(br s,3H,Me18),1.68(s,3H,Me19),1.23(s,3H,Me17),1.13(s,3H,Me16)。实施例4
用化合物(4)、(5)和(6),基本上按照Parness等人在J.Cell Biology 91:479-487(1981)中所述的方法进行微管蛋白结合测定(Tubulin binding assay),并与紫杉醇和taxotere进行了比较,结果见表1。
表1
微管蛋白测定化合物 Init, Rel.名称/式 Peak Rate4 2195 926 114紫杉醇 100 98Taxotere 100 -
实施例5
将紫杉烷4、5和6在体外评价它们抗人结肠癌细胞HCT-116和HCT-116/VM46的细胞毒活性。HCT116/VM细胞是已经选择teniposide抗性的细胞并表示出多药物抗性表型(multidrug resitancephenotype),包括对紫杉醇的抗性。细胞毒性在HCT 116和HCT VM46人结肠癌细胞中通过下述测定来评价:XTT(氢氧化2,3-双(2-甲氧基-4-硝基-5-磺苯基)-5-[(苯基氨基)羰基]-2H-四唑鎓测定(Scudiero等,“用人和其它肿瘤细胞系评价用于培养物中细胞生长和药物敏感性的可溶性四唑鎓/甲测定”,Cancer Res.48:4827-4833,1988)。将细胞以4000细胞/孔置于96孔微量滴定盘中。24小时后加入药物并连续稀释。将细胞于37℃培养72小时,同时加入四唑鎓染料XTT。在活细胞中的脱氢酶将XTT还原成在450nm处吸光的形式,它可用分光光度法定量。吸收越强,则活细胞的数目就越多。结果用IC50来表示,IC50是抑制细胞繁殖(即在450nm处的吸收)达未处理的对照细胞的50%时所需的药物浓度。结果见表2,数字越小表示活性越强。
表2
IC50
HCT HCT化合物名称/式
116 VM46
4 0.002 0.883
5 0.003 0.300
6 0.002 0.202紫杉醇 0.004 0.536Taxotere 0.007 0.246
鉴于以上所述,可以看出:本发明的几个目的已经达到。
由于不背离本发明的范围可对上述组合物进行各种改变,因此,以上说明书中所包含的所有内容均被理解为举例说明,并不具限定意义。
Claims (8)
T2是H、C1-C6烷基、C2-C6链烯基、C2-C6链炔基或单环芳基,Ac是乙酰基,以及E1和E2分别选自氢、羟基保护基团和基团-COGCOR1,其中
G是1,2-亚乙基、1,2-亚丙基、-CH=CH-、1,2-亚环己基或1,2-
亚苯基,
R1是NR2R3、OR3、SR3、OCH2CONR4R5或OH,
R2是氢、甲基,
R3是(CH2)nNR6R7、(CH2)nN+R6R7R8X-,
n是1-3,
R4是氢、具1-4个碳原子的低级烷基,
R5是氢、具1-4个碳原子的低级烷基、苄基、羟基乙基、
CH2CO2H、二甲基氨基乙基,R6R7是具1或2个碳原子的低级烷基、苄基或者R6与R7和
R8是具1或2个碳原子的低级烷基、苄基,
X-是卤离子。
2.权利要求1的紫杉烷衍生物,其中,T1是-COCH3,以及E1和E2是氢。
3.权利要求1的紫杉烷衍生物,其中,紫杉烷衍生物具2′R,3′S构型。
4.权利要求1的紫杉烷衍生物,其中,R1是苯基,T1是-COCH3,以及E1和E2中至少有一个是-COGCOR1,其中G是1,2-亚乙基、1,2-亚丙基、-CH=CH-、1,2-亚环己基或1,2-亚苯基,R1是NR2R3、OR3、SR3、OCH2CONR4R5或OH,R2是氢、甲基,R3是(CH2)nN6R7、(CH2)nN+R6R7R8X-,n是1-3,R4是氢、具1-4个碳原子的低级烷基,R5是氢、具1-4个碳原子的低级烷基、苄基、羟基乙基、CH2CO2H、二甲基氨基乙基,R6R7是具1或2个碳原子的低级烷基、苄基或者R6与R7和NR6R7中的氮原子一起形成下列环:R8是具1或2个碳原子的低级烷基、苄基,X-是卤离子。
5.权利要求1的紫杉烷衍生物,其中,T1是H或-COT2,T2是C1-C6烷基,以及E1和E2是氢,
8.一种药用组合物,它含有权利要求1的紫杉烷衍生物和一种或多种药学上可接受的、惰性或生理学上活性稀释剂或辅助剂。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US975,723 | 1992-11-13 | ||
US07/975,723 US5283253A (en) | 1991-09-23 | 1992-11-13 | Furyl or thienyl carbonyl substituted taxanes and pharmaceutical compositions containing them |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1094401A CN1094401A (zh) | 1994-11-02 |
CN1051310C true CN1051310C (zh) | 2000-04-12 |
Family
ID=25523314
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN93114654A Expired - Fee Related CN1051310C (zh) | 1992-11-13 | 1993-11-13 | 呋喃基或噻吩基羰基取代的紫杉烷及含它们的药用组合物 |
Country Status (15)
Country | Link |
---|---|
US (1) | US5283253A (zh) |
EP (1) | EP0669918B1 (zh) |
JP (1) | JP3328286B2 (zh) |
CN (1) | CN1051310C (zh) |
AT (1) | ATE176466T1 (zh) |
AU (1) | AU682161B2 (zh) |
CA (1) | CA2147859A1 (zh) |
DE (1) | DE69323436T2 (zh) |
DK (1) | DK0669918T3 (zh) |
ES (1) | ES2130390T3 (zh) |
GR (1) | GR3030129T3 (zh) |
IL (1) | IL107553A (zh) |
MX (1) | MX9307052A (zh) |
WO (1) | WO1994011362A1 (zh) |
ZA (1) | ZA938214B (zh) |
Families Citing this family (124)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5728725A (en) * | 1991-09-23 | 1998-03-17 | Florida State University | C2 taxane derivaties and pharmaceutical compositions containing them |
US6028205A (en) * | 1991-09-23 | 2000-02-22 | Florida State University | C2 tricyclic taxanes |
US6335362B1 (en) | 1991-09-23 | 2002-01-01 | Florida State University | Taxanes having an alkyl substituted side-chain and pharmaceutical compositions containing them |
US6794523B2 (en) | 1991-09-23 | 2004-09-21 | Florida State University | Taxanes having t-butoxycarbonyl substituted side-chains and pharmaceutical compositions containing them |
US5728850A (en) * | 1991-09-23 | 1998-03-17 | Florida State University | Taxanes having a butenyl substituted side-chain and pharmaceutical compositions containing them |
US5721268A (en) * | 1991-09-23 | 1998-02-24 | Florida State University | C7 taxane derivatives and pharmaceutical compositions containing them |
US5489601A (en) * | 1991-09-23 | 1996-02-06 | Florida State University | Taxanes having a pyridyl substituted side-chain and pharmaceutical compositions containing them |
US5739362A (en) * | 1991-09-23 | 1998-04-14 | Florida State University | Taxanes having an alkoxy, alkenoxy or aryloxy substituted side-chain and pharmaceutical compositions containing them |
US6011056A (en) | 1991-09-23 | 2000-01-04 | Florida State University | C9 taxane derivatives and pharmaceutical compositions containing them |
US6018073A (en) * | 1991-09-23 | 2000-01-25 | Florida State University | Tricyclic taxanes having an alkoxy, alkenoxy or aryloxy substituted side-chain and pharmaceutical compositions containing them |
US6495704B1 (en) | 1991-09-23 | 2002-12-17 | Florida State University | 9-desoxotaxanes and process for the preparation of 9-desoxotaxanes |
US5478854A (en) * | 1992-10-01 | 1995-12-26 | Bristol-Myers Squibb Company | Deoxy taxols |
US5380751A (en) * | 1992-12-04 | 1995-01-10 | Bristol-Myers Squibb Company | 6,7-modified paclitaxels |
FR2698871B1 (fr) | 1992-12-09 | 1995-02-24 | Rhone Poulenc Rorer Sa | Nouveau taxoïdes, leur préparation et les compositions pharmaceutiques qui les contiennent. |
US5973160A (en) * | 1992-12-23 | 1999-10-26 | Poss; Michael A. | Methods for the preparation of novel sidechain-bearing taxanes |
US5646176A (en) | 1992-12-24 | 1997-07-08 | Bristol-Myers Squibb Company | Phosphonooxymethyl ethers of taxane derivatives |
US6710191B2 (en) * | 1993-03-05 | 2004-03-23 | Florida State University | 9β-hydroxytetracyclic taxanes |
DK0687260T3 (da) * | 1993-03-05 | 2003-06-10 | Univ Florida State | Fremgangsmåde til fremstillingen af 9-desoxotaxaner |
US5703247A (en) * | 1993-03-11 | 1997-12-30 | Virginia Tech Intellectual Properties, Inc. | 2-Debenzoyl-2-acyl taxol derivatives and methods for making same |
SG73401A1 (en) * | 1993-03-22 | 2000-06-20 | Univ Florida State | Taxanes having alkoxy alkenoxy or aryloxy substituted side-chain and pharmaceutical compositions containing the same |
US5478860A (en) * | 1993-06-04 | 1995-12-26 | Inex Pharmaceuticals Corp. | Stable microemulsions for hydrophobic compound delivery |
EP0706376B2 (en) * | 1993-07-19 | 2007-08-08 | Angiotech Pharmaceuticals, Inc. | Anti-angiogenic compositions and methods of use |
US5677470A (en) | 1994-06-28 | 1997-10-14 | Tanabe Seiyaku Co., Ltd. | Baccatin derivatives and processes for preparing the same |
CA2162759A1 (en) * | 1994-11-17 | 1996-05-18 | Kenji Tsujihara | Baccatin derivatives and processes for preparing the same |
CA2178541C (en) * | 1995-06-07 | 2009-11-24 | Neal E. Fearnot | Implantable medical device |
US5780653A (en) * | 1995-06-07 | 1998-07-14 | Vivorx Pharmaceuticals, Inc. | Nitrophenyl, 10-deacetylated substituted taxol derivatives as dual functional cytotoxic/radiosensitizers |
CN1211919A (zh) | 1995-09-13 | 1999-03-24 | 佛罗里达州立大学 | 放射增敏性紫杉烷及其药物制剂 |
US5840748A (en) * | 1995-10-02 | 1998-11-24 | Xechem International, Inc. | Dihalocephalomannine and methods of use therefor |
US5854278A (en) * | 1995-12-13 | 1998-12-29 | Xechem International, Inc. | Preparation of chlorinated paclitaxel analogues and use thereof as antitumor agents |
US5807888A (en) * | 1995-12-13 | 1998-09-15 | Xechem International, Inc. | Preparation of brominated paclitaxel analogues and their use as effective antitumor agents |
US5654448A (en) * | 1995-10-02 | 1997-08-05 | Xechem International, Inc. | Isolation and purification of paclitaxel from organic matter containing paclitaxel, cephalomannine and other related taxanes |
US6177456B1 (en) | 1995-10-02 | 2001-01-23 | Xechem International, Inc. | Monohalocephalomannines having anticancer and antileukemic activity and method of preparation therefor |
WO1997042181A1 (en) * | 1996-05-06 | 1997-11-13 | Florida State University | 1-deoxy baccatin iii, 1-deoxy taxol and 1-deoxy taxol analogs and method for the preparation thereof |
US5635531A (en) * | 1996-07-08 | 1997-06-03 | Bristol-Myers Squibb Company | 3'-aminocarbonyloxy paclitaxels |
US5811452A (en) * | 1997-01-08 | 1998-09-22 | The Research Foundation Of State University Of New York | Taxoid reversal agents for drug-resistance in cancer chemotherapy and pharmaceutical compositions thereof |
US6156789A (en) * | 1998-03-17 | 2000-12-05 | Rhone-Poulenc Rorer S.A. | Method for treating abnormal cell proliferation in the brain |
US6136988A (en) | 1998-04-10 | 2000-10-24 | Hauser, Inc. | 7-hexanoyltaxol and methods for preparing the same |
US6333347B1 (en) * | 1999-01-29 | 2001-12-25 | Angiotech Pharmaceuticals & Advanced Research Tech | Intrapericardial delivery of anti-microtubule agents |
EP2289549A3 (en) | 1999-10-01 | 2011-06-15 | Immunogen, Inc. | Immunoconjugates for treating cancer |
US6649632B2 (en) * | 2000-02-02 | 2003-11-18 | Fsu Research Foundation, Inc. | C10 ester substituted taxanes |
AU776767B2 (en) | 2000-02-02 | 2004-09-23 | Florida State University Research Foundation, Inc. | C10 heterosubstituted acetate taxanes as antitumor agents |
JP2003522171A (ja) | 2000-02-02 | 2003-07-22 | フロリダ・ステイト・ユニバーシティ・リサーチ・ファウンデイション・インコーポレイテッド | 抗腫瘍剤としてのc10カーボネート置換タキサン |
ATE392422T1 (de) * | 2000-02-02 | 2008-05-15 | Univ Florida State Res Found | C7-carbamoyloxysubstituierte taxane als antitumormittel |
ATE413397T1 (de) * | 2000-02-02 | 2008-11-15 | Univ Florida State Res Found | Heterosubstituierte c7-taxanacetate als antitumormittel |
WO2001057033A1 (en) * | 2000-02-02 | 2001-08-09 | Florida State University Research Foundation, Inc. | C10 carbamoyloxy substituted taxanes as antitumor agents |
CO5280224A1 (es) * | 2000-02-02 | 2003-05-30 | Univ Florida State Res Found | Taxanos sustituidos con ester en c7, utiles como agentes antitumorales y composiciones farmaceuticas que los contienen |
CA2367661A1 (en) * | 2000-02-02 | 2001-08-09 | Robert A. Holton | Taxane formulations having improved solubility |
AU776122B2 (en) * | 2000-02-02 | 2004-08-26 | Florida State University Research Foundation, Inc. | C7 carbonate substituted taxanes as antitumor agents |
US6916942B2 (en) * | 2000-02-03 | 2005-07-12 | Bristol-Myers Squibb Company | Process for the preparation of C-4 carbonate taxanes |
US6750246B1 (en) | 2000-02-03 | 2004-06-15 | Bristol-Myers Squibb Company | C-4 carbonate taxanes |
US6362217B2 (en) | 2000-03-17 | 2002-03-26 | Bristol-Myers Squibb Company | Taxane anticancer agents |
CA2307393A1 (en) | 2000-05-01 | 2001-11-01 | The University Of British Columbia | Ginsenoside chemotherapy |
EP1318794A2 (en) * | 2000-09-22 | 2003-06-18 | Bristol-Myers Squibb Company | Method for reducing toxicity of combined chemotherapies |
AU2002240755B2 (en) * | 2001-03-13 | 2007-07-05 | Angiotech International Ag | Micellar drug delivery vehicles and uses thereof |
US20030157170A1 (en) * | 2001-03-13 | 2003-08-21 | Richard Liggins | Micellar drug delivery vehicles and precursors thereto and uses thereof |
JP2004532847A (ja) | 2001-04-20 | 2004-10-28 | ザ ユニヴァーシティ オヴ ブリティッシュ コロンビア | 疎水性薬物のためのミセル薬物送達システム |
US20030216758A1 (en) * | 2001-12-28 | 2003-11-20 | Angiotech Pharmaceuticals, Inc. | Coated surgical patches |
US20040210289A1 (en) * | 2002-03-04 | 2004-10-21 | Xingwu Wang | Novel nanomagnetic particles |
US7351542B2 (en) | 2002-05-20 | 2008-04-01 | The Regents Of The University Of California | Methods of modulating tubulin deacetylase activity |
AU2003300076C1 (en) | 2002-12-30 | 2010-03-04 | Angiotech International Ag | Drug delivery from rapid gelling polymer composition |
US20040254419A1 (en) * | 2003-04-08 | 2004-12-16 | Xingwu Wang | Therapeutic assembly |
EP2390262A1 (en) | 2003-05-16 | 2011-11-30 | Intermune, Inc. | Synthetic chemokine receptor ligands and methods of use thereof |
US7064980B2 (en) * | 2003-09-17 | 2006-06-20 | Sandisk Corporation | Non-volatile memory and method with bit line coupled compensation |
US7407973B2 (en) * | 2003-10-24 | 2008-08-05 | Intermune, Inc. | Use of pirfenidone in therapeutic regimens |
US20070149496A1 (en) * | 2003-10-31 | 2007-06-28 | Jack Tuszynski | Water-soluble compound |
PE20050693A1 (es) * | 2004-02-13 | 2005-09-27 | Univ Florida State Res Found | Taxanos sustituidos con esteres de ciclopentilo en c10 |
CN1960721A (zh) | 2004-03-05 | 2007-05-09 | 佛罗里达州立大学研究基金有限公司 | C7乳酰氧基取代的紫杉烷类 |
US20050249667A1 (en) * | 2004-03-24 | 2005-11-10 | Tuszynski Jack A | Process for treating a biological organism |
US7846940B2 (en) * | 2004-03-31 | 2010-12-07 | Cordis Corporation | Solution formulations of sirolimus and its analogs for CAD treatment |
US8003122B2 (en) * | 2004-03-31 | 2011-08-23 | Cordis Corporation | Device for local and/or regional delivery employing liquid formulations of therapeutic agents |
US7989490B2 (en) * | 2004-06-02 | 2011-08-02 | Cordis Corporation | Injectable formulations of taxanes for cad treatment |
US7597884B2 (en) * | 2004-08-09 | 2009-10-06 | Alios Biopharma, Inc. | Hyperglycosylated polypeptide variants and methods of use |
KR20070085227A (ko) * | 2004-08-09 | 2007-08-27 | 앨리오스 바이오파마 인크. | 합성 초글리코실화, 프로테아제 저항성 폴리펩티드 변이체,경구 제제 및 이를 이용한 방법 |
TW200640447A (en) * | 2005-02-14 | 2006-12-01 | Univ Florida State Res Found | C10 cyclopropyl ester substituted taxane compositions |
WO2006089218A2 (en) * | 2005-02-17 | 2006-08-24 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and compositions for modulating angiogenesis |
US20070073385A1 (en) * | 2005-09-20 | 2007-03-29 | Cook Incorporated | Eluting, implantable medical device |
US20070196423A1 (en) * | 2005-11-21 | 2007-08-23 | Med Institute, Inc. | Implantable medical device coatings with biodegradable elastomer and releasable therapeutic agent |
CA2646156C (en) | 2006-03-22 | 2016-05-24 | Medigene Ag | Treatment of triple receptor negative breast cancer |
PL217731B1 (pl) | 2006-06-01 | 2014-08-29 | Tomasz Byrski | Sposób wykrywania genetycznie uwarunkowanej obniżonej odpowiedzi na chemioterapię cytostatykiem taksanowym, zastosowanie mutacji założycielskiej oraz zestawu do wykrywania takiej odpowiedzi |
EP2043704B2 (en) | 2006-06-30 | 2017-04-19 | Cook Medical Technologies LLC | Methods of manufacturing and modifying taxane coatings for implantable medical devices |
US20080161324A1 (en) * | 2006-09-14 | 2008-07-03 | Johansen Lisa M | Compositions and methods for treatment of viral diseases |
US20080241215A1 (en) * | 2007-03-28 | 2008-10-02 | Robert Falotico | Local vascular delivery of probucol alone or in combination with sirolimus to treat restenosis, vulnerable plaque, aaa and stroke |
US8409601B2 (en) | 2008-03-31 | 2013-04-02 | Cordis Corporation | Rapamycin coated expandable devices |
US8420110B2 (en) | 2008-03-31 | 2013-04-16 | Cordis Corporation | Drug coated expandable devices |
WO2009145981A1 (en) * | 2008-03-31 | 2009-12-03 | Florida State University Research Foundation, Inc. | C(10) ethyl ester and c(10) cyclopropyl ester substituted taxanes |
US8273404B2 (en) * | 2008-05-19 | 2012-09-25 | Cordis Corporation | Extraction of solvents from drug containing polymer reservoirs |
WO2009143454A2 (en) | 2008-05-22 | 2009-11-26 | Kereos, Inc. | Combination antitumor therapy |
WO2010005850A1 (en) | 2008-07-08 | 2010-01-14 | The J. David Gladstone Institutes | Methods and compositions for modulating angiogenesis |
US8642063B2 (en) * | 2008-08-22 | 2014-02-04 | Cook Medical Technologies Llc | Implantable medical device coatings with biodegradable elastomer and releasable taxane agent |
US8354435B2 (en) | 2008-09-08 | 2013-01-15 | The Board Of Trustees Of The Leland Stanford Junior University | Modulators of aldehyde dehydrogenase activity and methods of use thereof |
US9198968B2 (en) | 2008-09-15 | 2015-12-01 | The Spectranetics Corporation | Local delivery of water-soluble or water-insoluble therapeutic agents to the surface of body lumens |
US8389522B2 (en) | 2008-10-28 | 2013-03-05 | The Board Of Trustees Of The Leland Stanford Junior University | Modulators of aldehyde dehydrogenase and methods of use thereof |
WO2012149106A1 (en) | 2011-04-29 | 2012-11-01 | The Board Of Trustees Of The Leland Stanford Junior University | Compositions and methods for increasing proliferation of adult salivary stem cells |
US20120303115A1 (en) | 2011-05-25 | 2012-11-29 | Dadino Ronald C | Expandable devices coated with a rapamycin composition |
US20120302954A1 (en) | 2011-05-25 | 2012-11-29 | Zhao Jonathon Z | Expandable devices coated with a paclitaxel composition |
US9956385B2 (en) | 2012-06-28 | 2018-05-01 | The Spectranetics Corporation | Post-processing of a medical device to control morphology and mechanical properties |
IN2015DN00552A (zh) | 2012-07-19 | 2015-06-26 | Redwood Bioscience Inc | |
EP2916835A4 (en) | 2012-11-12 | 2016-07-27 | Redwood Bioscience Inc | COMPOUNDS AND METHOD FOR PRODUCING A CONJUGATE |
PT3613439T (pt) | 2013-02-15 | 2021-05-12 | Univ California | Recetor de antigénio quimérico e métodos de utilização do mesmo |
US9670162B2 (en) | 2013-03-14 | 2017-06-06 | The Board Of Trustees Of The Leland Stanford Junio | Mitochondrial aldehyde dehyrogenase-2 modulators and methods of use thereof |
AU2014354643B2 (en) | 2013-11-27 | 2020-03-05 | Redwood Bioscience, Inc. | Hydrazinyl-pyrrolo compounds and methods for producing a conjugate |
CA2940269C (en) | 2014-02-19 | 2022-08-16 | Aviv Therapeutics, Inc. | Mitochondrial aldehyde dehydrogenase 2 (aldh2) binding polycyclic amides and their use for the treatment of cancer |
KR20180058759A (ko) | 2015-09-25 | 2018-06-01 | 제트와이 테라퓨틱스 인코포레이티드 | 폴리사카라이드-비타민 접합체를 포함하는 미립자를 기재로 하는 약물 제제 |
US10654875B2 (en) | 2015-11-12 | 2020-05-19 | The Board Of Trustees Of The Leland Stanford Junior University | Cell-penetrating, guanidinium-rich oligophosphotriesters for drug and probe delivery |
TWI760319B (zh) | 2015-12-30 | 2022-04-11 | 杏國新藥股份有限公司 | 乳癌治療 |
UA123020C2 (uk) | 2016-06-01 | 2021-02-03 | Сервьє Айпі Юкей Лімітед | Склади поліалкіленоксид-аспарагінази та способи їхнього виготовлення й використання |
TW201825087A (zh) | 2017-01-05 | 2018-07-16 | 杏國新藥股份有限公司 | 胰臟癌治療 |
KR20190130559A (ko) | 2017-01-18 | 2019-11-22 | 에프1 온콜로지, 인코포레이티드 | Axl 또는 ror2에 대한 키메라 항원 수용체 및 이의 사용 방법 |
EP3388082A1 (en) | 2017-04-13 | 2018-10-17 | Galera Labs, LLC | Combination cancer immunotherapy with pentaaza macrocyclic ring complex |
AU2019215032A1 (en) | 2018-01-31 | 2020-09-10 | Board Of Regents Of The University Of Texas System | Combination cancer therapy with pentaaza macrocyclic ring complex and platinum-based anticancer agent |
CN112368011A (zh) | 2018-04-11 | 2021-02-12 | 俄亥俄州创新基金会 | 缓释微粒用于眼用药物递送的方法和组合物 |
JP2021530507A (ja) | 2018-07-18 | 2021-11-11 | マンザニータ ファーマシューティカルズ,インク. | 神経細胞に抗がん剤を送達するためのコンジュゲート、その使用方法及び製造方法 |
TW202038994A (zh) | 2019-01-14 | 2020-11-01 | 美商醫格耐免疫治療公司 | 重組痘瘡病毒及其使用方法 |
EP3923967A1 (en) | 2019-02-14 | 2021-12-22 | Ignite Immunotherapy, Inc. | Recombinant vaccinia virus and methods of use thereof |
MX2021012003A (es) | 2019-04-02 | 2021-11-04 | Kenjockety Biotechnology Inc | Anticuerpos multiespecificos contra antigeno de cancer de la bomba de eflujo y composiciones, reactivos, kits y metodos relacionados con los mismos. |
JP2021106576A (ja) | 2019-12-12 | 2021-07-29 | イグナイト・イミュノセラピー,インコーポレーテッド | 変異体腫瘍溶解性ワクシニアウイルスおよびその使用法 |
EP4097134A1 (en) | 2020-01-29 | 2022-12-07 | Kenjockety Biotechnology, Inc. | Anti-mdr1 antibodies and uses thereof |
WO2021247423A1 (en) | 2020-06-04 | 2021-12-09 | Kenjockety Biotechnology, Inc. | Abcg2 efflux pump-cancer antigen multi-specific antibodies and compositions, reagents, kits and methods related thereto |
CN116323662A (zh) | 2020-06-04 | 2023-06-23 | 肯乔克蒂生物技术股份有限公司 | 抗abcg2抗体及其用途 |
BR112023000650A2 (pt) | 2020-07-14 | 2023-01-31 | Pfizer | Vírus vaccinia recombinante |
CN116490522A (zh) | 2020-09-02 | 2023-07-25 | 肯乔克蒂生物技术股份有限公司 | 抗abcc1抗体及其应用 |
CA3203652A1 (en) | 2020-11-13 | 2022-05-19 | William Robert ARATHOON | Anti-mrp4 (encoded by abcc4 gene) antibodies and uses thereof |
WO2023114658A1 (en) | 2021-12-13 | 2023-06-22 | Kenjockety Biotechnology, Inc. | Anti-abcb1 antibodies |
WO2023159220A1 (en) | 2022-02-18 | 2023-08-24 | Kenjockety Biotechnology, Inc. | Anti-cd47 antibodies |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4942184A (en) * | 1988-03-07 | 1990-07-17 | The United States Of America As Represented By The Department Of Health And Human Services | Water soluble, antineoplastic derivatives of taxol |
US4960790A (en) * | 1989-03-09 | 1990-10-02 | University Of Kansas | Derivatives of taxol, pharmaceutical compositions thereof and methods for the preparation thereof |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU601180B2 (en) * | 1986-04-30 | 1990-09-06 | Kanegafuchi Kagaku Kogyo Kabushiki Kaisha | Process for preparing 4-acetoxy-3-hydroxyethylazetidin -2- one derivatives |
FR2601676B1 (fr) * | 1986-07-17 | 1988-09-23 | Rhone Poulenc Sante | Procede de preparation du taxol et du desacetyl-10 taxol |
FR2601675B1 (fr) * | 1986-07-17 | 1988-09-23 | Rhone Poulenc Sante | Derives du taxol, leur preparation et les compositions pharmaceutiques qui les contiennent |
FR2629819B1 (fr) * | 1988-04-06 | 1990-11-16 | Rhone Poulenc Sante | Procede de preparation de derives de la baccatine iii et de la desacetyl-10 baccatine iii |
FR2629818B1 (fr) * | 1988-04-06 | 1990-11-16 | Centre Nat Rech Scient | Procede de preparation du taxol |
US5175315A (en) * | 1989-05-31 | 1992-12-29 | Florida State University | Method for preparation of taxol using β-lactam |
US5015744A (en) * | 1989-11-14 | 1991-05-14 | Florida State University | Method for preparation of taxol using an oxazinone |
US5136060A (en) * | 1989-11-14 | 1992-08-04 | Florida State University | Method for preparation of taxol using an oxazinone |
US5059699A (en) * | 1990-08-28 | 1991-10-22 | Virginia Tech Intellectual Properties, Inc. | Water soluble derivatives of taxol |
MX9102128A (es) * | 1990-11-23 | 1992-07-08 | Rhone Poulenc Rorer Sa | Derivados de taxano,procedimiento para su preparacion y composicion farmaceutica que los contiene |
-
1992
- 1992-11-13 US US07/975,723 patent/US5283253A/en not_active Expired - Lifetime
-
1993
- 1993-11-01 WO PCT/US1993/010473 patent/WO1994011362A1/en active IP Right Grant
- 1993-11-01 AU AU55450/94A patent/AU682161B2/en not_active Ceased
- 1993-11-01 ES ES94900474T patent/ES2130390T3/es not_active Expired - Lifetime
- 1993-11-01 EP EP94900474A patent/EP0669918B1/en not_active Expired - Lifetime
- 1993-11-01 AT AT94900474T patent/ATE176466T1/de not_active IP Right Cessation
- 1993-11-01 DK DK94900474T patent/DK0669918T3/da active
- 1993-11-01 DE DE69323436T patent/DE69323436T2/de not_active Expired - Fee Related
- 1993-11-01 JP JP51214994A patent/JP3328286B2/ja not_active Expired - Fee Related
- 1993-11-01 CA CA002147859A patent/CA2147859A1/en not_active Abandoned
- 1993-11-03 ZA ZA938214A patent/ZA938214B/xx unknown
- 1993-11-10 IL IL107553A patent/IL107553A/xx not_active IP Right Cessation
- 1993-11-11 MX MX9307052A patent/MX9307052A/es not_active IP Right Cessation
- 1993-11-13 CN CN93114654A patent/CN1051310C/zh not_active Expired - Fee Related
-
1999
- 1999-04-30 GR GR990401211T patent/GR3030129T3/el unknown
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4942184A (en) * | 1988-03-07 | 1990-07-17 | The United States Of America As Represented By The Department Of Health And Human Services | Water soluble, antineoplastic derivatives of taxol |
US4960790A (en) * | 1989-03-09 | 1990-10-02 | University Of Kansas | Derivatives of taxol, pharmaceutical compositions thereof and methods for the preparation thereof |
Also Published As
Publication number | Publication date |
---|---|
IL107553A0 (en) | 1994-02-27 |
DE69323436T2 (de) | 1999-09-09 |
MX9307052A (es) | 1994-05-31 |
DK0669918T3 (da) | 1999-09-20 |
ES2130390T3 (es) | 1999-07-01 |
IL107553A (en) | 1997-11-20 |
AU682161B2 (en) | 1997-09-25 |
ZA938214B (en) | 1994-07-19 |
WO1994011362A1 (en) | 1994-05-26 |
AU5545094A (en) | 1994-06-08 |
EP0669918A4 (en) | 1995-07-10 |
DE69323436D1 (de) | 1999-03-18 |
JPH08502995A (ja) | 1996-04-02 |
EP0669918A1 (en) | 1995-09-06 |
CN1094401A (zh) | 1994-11-02 |
EP0669918B1 (en) | 1999-02-03 |
ATE176466T1 (de) | 1999-02-15 |
US5283253A (en) | 1994-02-01 |
CA2147859A1 (en) | 1994-05-26 |
GR3030129T3 (en) | 1999-07-30 |
JP3328286B2 (ja) | 2002-09-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1051310C (zh) | 呋喃基或噻吩基羰基取代的紫杉烷及含它们的药用组合物 | |
US5284864A (en) | Butenyl substituted taxanes and pharmaceutical compositions containing them | |
CA2158862C (en) | Taxanes having alkoxy, alkenoxy or aryloxy substituted side-chain and pharmaceutical compositions containing same | |
CA2155013C (en) | C2 taxane derivatives and pharmaceutical compositions containing them | |
EP1146043A1 (en) | Taxanes having an alkyl substituted side-chain and pharmaceutical compositions containing them | |
IL108316A (en) | History of C-10 Texan and pharmaceuticals containing them | |
JP3759601B2 (ja) | アミノ置換側鎖を有するタキサン | |
US6339164B1 (en) | C2 substituted phenyl taxane derivatives and pharmaceutical compositions containing them | |
CA2158863C (en) | Taxanes having a pyridyl substituted side-chain | |
CA2147854C (en) | Taxanes having an alkyl substituted side-chain and pharmaceutical compositions containing them |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C19 | Lapse of patent right due to non-payment of the annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |